This study is looking at a new treatment called VG712 for people with mycosis fungoides (MF), a type of skin lymphoma. VG712 works by targeting and removing certain immune cells (CD3-positive T cells) that may be involved in the disease. Researchers want to see if VG712 is safe and effective compared to an existing treatment called mogamulizumab. You might be able to join if you are 18 or older, have mycosis fungoides that has come back or hasn't responded to at least two other treatments, and do not have Sézary syndrome. The main goal is to see how long people live without their disease getting worse (Progression-Free Survival), which will be tracked for up to 72 months after treatment ends. The study is currently recruiting participants.

Study design

This is a Phase 2 study with two parts. The first part will determine the best dose of VG712 in up to 24 people, followed by a larger part where about 322 people will be randomly assigned to receive either VG712 or mogamulizumab.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed to track Progression-Free Survival until disease progression or death, for up to 72 months after their end-of-treatment visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.